Anti-CD80 [IDEC-114 (Galiximab)]

Absolute Antibody

Anti-CD80 [IDEC-114 (Galiximab)]

7

Galiximab acts to decrease in cell proliferation, inhibition of the constitutively active NF-kappaB pathway, increase in apoptosis and ADCC against various B-cell lymphoma cell lines. Galiximb affects CD28 and CD152 interactions with CD80. This antibody can also be used for FC, WB, ELISA, IP and IHC.

Flow Cytometry, ImmunoPrecipitation, Western Blot, ELISA, ImmunoHistoChemistry, Neutralisation/Blocking

block; modulate; FC; WB; ELISA; IP; IHC

Research Use Only

Monoclonal

IDEC-114 (Galiximab)

CD80

CD80 molecule

activation B7-1 antigen; B7; B7.1; B7-1; BB1; B-lymphocyte activation antigen B7; CD28LG; CD28LG1; CD80 antigen (CD28 antigen ligand 1, B7-1 antigen); costimulatory factor CD80; costimulatory molecule variant IgV-CD80; CTLA-4 counter-receptor B7.1; LAB7; T-lymphocyte activation antigen CD80

Human

IgG1

T-lymphocyte activation antigen CD80

Human

Galiximab was prepared by immunizing cynomolgus monkeys with recombinant CD80 antigen. The variable regions of the light and heavy chains were then cloned by being incorporated into a cassette vector (N5LG1) containing human constant region genes and subsequently transfected into the Dg44 CHO cell line (Hariharan K, 2013)

-20°C,2°C to 8°C

12352203